Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2016

01.08.2016 | Research Article

Prescribing patterns of non-steroidal anti-inflammatory drugs in chronic kidney disease patients in the South African private sector

verfasst von: Willem P. Meuwesen, Jesslee M. du Plessis, Johanita R. Burger, Martie S. Lubbe, Marike Cockeran

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Background Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used pharmaceutical agents worldwide. NSAIDs are considered nephrotoxic and should therefore be used with caution or be avoided completely in high risk patients, such as chronic kidney disease (CKD) patients. Objective This study aimed to investigate the prescribing of NSAIDs in CKD patients in order to generate awareness and improve the outcome of these patients. Setting The study was conducted using medicine claims data in the private health sector of South Africa. Method A descriptive, quantitative study was performed, using retrospective data obtained from a Pharmaceutical Benefit Management company. Data from 1 January 2009 to 31 December 2013 were analysed. The study population consisted of all patients with an ICD-10 code for a CKD (N18), in association with a paid claim for an NSAID. Main outcome measure The stratification of NSAID prescribing volume among the CKD population in terms of gender, age, NSAID type, dosage and prescriber type. Results The prescribing of NSAIDs in CKD patients varied between 26 and 40 % over the 5 year study period. No association between gender and CKD patients who received NSAIDs versus those who did not was found, with p > 0.05 and Cramer’s V < 0.1 for each year of the study. The association between age groups and CKD patients who received NSAIDs versus those who did not was statistically significant, but practically weak (p < 0.05; Cramer’s V ≥ 0.1). Most NSAID prescriptions (52–63 %) were for patients aged 35–64 years. Diclofenac (34.25 %) was the single most frequently prescribed NSAID, but the COX-2-inhibitors (celecoxib, meloxicam and etoricoxib) were the preferred NSAID class to be prescribed. The majority (61.6 %) of the NSAIDs were prescribed by general medical practitioners in dosages meeting and even exceeding the recommended daily dosage of patients with normal kidney function. Conclusions Even though NSAIDs are regarded as nephrotoxic drugs, they are still being prescribed to at-risk CKD patients, in particular, the elderly.
Literatur
1.
Zurück zum Zitat Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol. 2006;25:S22–9.CrossRefPubMed Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol. 2006;25:S22–9.CrossRefPubMed
2.
Zurück zum Zitat Paul AD, Chauhan CK. Study of usage of nonsteroidal anti-inflammatory drugs (NSAIDs) among different practice categories in Indian clinical setting. Eur J Clin Pharmacol. 2005;60:889–92.CrossRefPubMed Paul AD, Chauhan CK. Study of usage of nonsteroidal anti-inflammatory drugs (NSAIDs) among different practice categories in Indian clinical setting. Eur J Clin Pharmacol. 2005;60:889–92.CrossRefPubMed
4.
Zurück zum Zitat Tsai HJ, Hsu YH, Huang YW, Chang YK, Liu JS, Hsu CC. Use of non-steroidal anti-inflammatory drugs and risk of chronic kidney disease in people with type 2 diabetes mellitus, a nationwide longitudinal cohort study. Diabet Med. 2015;32:382–90.CrossRefPubMed Tsai HJ, Hsu YH, Huang YW, Chang YK, Liu JS, Hsu CC. Use of non-steroidal anti-inflammatory drugs and risk of chronic kidney disease in people with type 2 diabetes mellitus, a nationwide longitudinal cohort study. Diabet Med. 2015;32:382–90.CrossRefPubMed
5.
Zurück zum Zitat Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247–55.CrossRefPubMed Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247–55.CrossRefPubMed
6.
Zurück zum Zitat Plantinga L, Grubbs V, Sarkar U. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Family Med. 2011;9(5):423–30.CrossRef Plantinga L, Grubbs V, Sarkar U. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Family Med. 2011;9(5):423–30.CrossRef
8.
Zurück zum Zitat Santoro D, Satta E, Messina S, Costantino G, Savica V, Bellinghieri G. Pain in end-stage renal disease: a frequent and neglected clinical problem. Clin Rheumatol. 2012;78(1):S2–11. Santoro D, Satta E, Messina S, Costantino G, Savica V, Bellinghieri G. Pain in end-stage renal disease: a frequent and neglected clinical problem. Clin Rheumatol. 2012;78(1):S2–11.
9.
Zurück zum Zitat Cohen SD, Patel SS, Khetpal P, Peterson RA, Kimmel PL. Pain, sleep disturbance and quality of life in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:919–25.CrossRefPubMed Cohen SD, Patel SS, Khetpal P, Peterson RA, Kimmel PL. Pain, sleep disturbance and quality of life in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:919–25.CrossRefPubMed
10.
Zurück zum Zitat Kafkia T, Chamney M, Drinkwater A, Pegoraro M, Sedgewick J. Pain in chronic kidney disease: prevalence, cause and management. J Ren Care. 2011;37(2):114–22.CrossRefPubMed Kafkia T, Chamney M, Drinkwater A, Pegoraro M, Sedgewick J. Pain in chronic kidney disease: prevalence, cause and management. J Ren Care. 2011;37(2):114–22.CrossRefPubMed
12.
13.
Zurück zum Zitat Ahmed Z, Simon B, Choudhury D. Management of diabetes in patients with chronic kidney disease. Postgrad Med. 2009;121(3):52–60.CrossRefPubMed Ahmed Z, Simon B, Choudhury D. Management of diabetes in patients with chronic kidney disease. Postgrad Med. 2009;121(3):52–60.CrossRefPubMed
14.
Zurück zum Zitat Loh AHL, Cohen AH. Drug-induced kidney disease–pathology and current concepts. Ann Acad Med. 2009;38:240–50. Loh AHL, Cohen AH. Drug-induced kidney disease–pathology and current concepts. Ann Acad Med. 2009;38:240–50.
19.
Zurück zum Zitat Snyman, J.R., ed. 2015. Monthly Index of Medicine Specialities, 55th ed. Johannesburg: MPASA. Snyman, J.R., ed. 2015. Monthly Index of Medicine Specialities, 55th ed. Johannesburg: MPASA.
20.
Zurück zum Zitat Rossiter D, editor. South African Medicine Formulary. 11th ed. Cape Town: Health and Medical; 2014. Rossiter D, editor. South African Medicine Formulary. 11th ed. Cape Town: Health and Medical; 2014.
21.
Zurück zum Zitat Bhopal S, Chan J, Ellis O. Non-steroidal anti-inflammatory drugs prescribing in chronic kidney disease: an observational study. Prim Health Care Res Dev. 2010;11(3):280–4.CrossRef Bhopal S, Chan J, Ellis O. Non-steroidal anti-inflammatory drugs prescribing in chronic kidney disease: an observational study. Prim Health Care Res Dev. 2010;11(3):280–4.CrossRef
22.
Zurück zum Zitat Ingrasciotta Y, Sultana J, Giorgianni F. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS ONE. 2014;9(2):1–8.CrossRef Ingrasciotta Y, Sultana J, Giorgianni F. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS ONE. 2014;9(2):1–8.CrossRef
23.
Zurück zum Zitat Gluhovschi GH, Gluhovschi A, Anastasiu D, Petrica L, Gluhocschi C, Velciov S. Chronic kidney disease and the involvement of estrogen hormones in its pathogenesis and progression. Rom J Intern Med. 2012;50(2):135–44.PubMed Gluhovschi GH, Gluhovschi A, Anastasiu D, Petrica L, Gluhocschi C, Velciov S. Chronic kidney disease and the involvement of estrogen hormones in its pathogenesis and progression. Rom J Intern Med. 2012;50(2):135–44.PubMed
25.
Zurück zum Zitat Otero A, de Francisco ALM, Gayoso P, Garcίa F. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia. 2010;30(1):78–86.PubMed Otero A, de Francisco ALM, Gayoso P, Garcίa F. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia. 2010;30(1):78–86.PubMed
26.
Zurück zum Zitat Zhang Q, Koenig W, Raum E, Stegmaier C, Brenner H, Rothenbacher D. Epidemiology of chronic kidney disease: results from a population of older adults in Germany. Prev Med. 2009;48:122–7.CrossRefPubMed Zhang Q, Koenig W, Raum E, Stegmaier C, Brenner H, Rothenbacher D. Epidemiology of chronic kidney disease: results from a population of older adults in Germany. Prev Med. 2009;48:122–7.CrossRefPubMed
27.
Zurück zum Zitat Tomson C, Bailey P. Management of chronic kidney disease. Medicine. 2011;39(7):407–13.CrossRef Tomson C, Bailey P. Management of chronic kidney disease. Medicine. 2011;39(7):407–13.CrossRef
30.
Zurück zum Zitat Howse MLP, Bell GM. Drugs and toxins that damage the kidney. Medicine. 2007;35(7):399–403.CrossRef Howse MLP, Bell GM. Drugs and toxins that damage the kidney. Medicine. 2007;35(7):399–403.CrossRef
31.
Zurück zum Zitat Hunter LJ, Wood DM, Dargan PI. The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open Access Emerg Med. 2011;3:39–48.CrossRefPubMedPubMedCentral Hunter LJ, Wood DM, Dargan PI. The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open Access Emerg Med. 2011;3:39–48.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int. 2010;107(37):647–56.PubMedPubMedCentral Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int. 2010;107(37):647–56.PubMedPubMedCentral
Metadaten
Titel
Prescribing patterns of non-steroidal anti-inflammatory drugs in chronic kidney disease patients in the South African private sector
verfasst von
Willem P. Meuwesen
Jesslee M. du Plessis
Johanita R. Burger
Martie S. Lubbe
Marike Cockeran
Publikationsdatum
01.08.2016
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2016
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0298-1

Weitere Artikel der Ausgabe 4/2016

International Journal of Clinical Pharmacy 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.